115 related articles for article (PubMed ID: 28881610)
1. Association between rs2853669 in TERT gene and the risk and prognosis of human cancer: a systematic review and meta-analysis.
Shen N; Lu Y; Wang X; Peng J; Zhu Y; Cheng L
Oncotarget; 2017 Aug; 8(31):50864-50872. PubMed ID: 28881610
[TBL] [Abstract][Full Text] [Related]
2. The prognostic impact of TERT promoter mutations in glioblastomas is modified by the rs2853669 single nucleotide polymorphism.
Batista R; Cruvinel-Carloni A; Vinagre J; Peixoto J; Catarino TA; Campanella NC; Menezes W; Becker AP; de Almeida GC; Matsushita MM; Clara C; Neder L; Viana-Pereira M; Honavar M; Castro L; Lopes JM; Carvalho B; Vaz RM; Máximo V; Soares P; Sobrinho-Simões M; Reis RM; Lima J
Int J Cancer; 2016 Jul; 139(2):414-23. PubMed ID: 26914704
[TBL] [Abstract][Full Text] [Related]
3. TERT promoter mutations and rs2853669 polymorphism: prognostic impact and interactions with common alterations in glioblastomas.
Nencha U; Rahimian A; Giry M; Sechi A; Mokhtari K; Polivka M; Schmitt Y; Di Stefano AL; Alentorn A; Labussière M; Sanson M
J Neurooncol; 2016 Feb; 126(3):441-6. PubMed ID: 26608520
[TBL] [Abstract][Full Text] [Related]
4. Human TERT promoter polymorphism rs2853669 is associated with cancers: an updated meta-analysis.
Aziz MA; Jafrin S; Islam MS
Hum Cell; 2021 Jul; 34(4):1066-1081. PubMed ID: 33743166
[TBL] [Abstract][Full Text] [Related]
5. Association between functional TERT promoter polymorphism rs2853669 and cervical cancer risk in South Indian women.
Vinothkumar V; Arun K; Arunkumar G; Revathidevi S; Ramani R; Bhaskar LVKS; Murugan AK; Munirajan AK
Mol Clin Oncol; 2020 May; 12(5):485-494. PubMed ID: 32257207
[TBL] [Abstract][Full Text] [Related]
6. Association between TERT rs2853669 polymorphism and cancer risk: A meta-analysis of 9,157 cases and 11,073 controls.
Liu Z; Wang T; Wu Z; Zhang K; Li W; Yang J; Chen C; Chen L; Xing J
PLoS One; 2018; 13(3):e0191560. PubMed ID: 29534075
[TBL] [Abstract][Full Text] [Related]
7. Prognostic quality of activating TERT promoter mutations in glioblastoma: interaction with the rs2853669 polymorphism and patient age at diagnosis.
Spiegl-Kreinecker S; Lötsch D; Ghanim B; Pirker C; Mohr T; Laaber M; Weis S; Olschowski A; Webersinke G; Pichler J; Berger W
Neuro Oncol; 2015 Sep; 17(9):1231-40. PubMed ID: 25681309
[TBL] [Abstract][Full Text] [Related]
8. The TERT promoter SNP rs2853669 decreases E2F1 transcription factor binding and increases mortality and recurrence risks in liver cancer.
Ko E; Seo HW; Jung ES; Kim BH; Jung G
Oncotarget; 2016 Jan; 7(1):684-99. PubMed ID: 26575952
[TBL] [Abstract][Full Text] [Related]
9. The prognostic significance of TERT promoter mutations in meningioma: a systematic review and meta-analysis.
Lu VM; Goyal A; Lee A; Jentoft M; Quinones-Hinojosa A; Chaichana KL
J Neurooncol; 2019 Mar; 142(1):1-10. PubMed ID: 30506498
[TBL] [Abstract][Full Text] [Related]
10. TERT promoter mutations in soft tissue sarcomas.
Campanella NC; Penna V; Abrahão-Machado LF; Cruvinel-Carloni A; Ribeiro G; Soares P; Scapulatempo-Neto C; Reis RM
Int J Biol Markers; 2016 Feb; 31(1):e62-7. PubMed ID: 26391479
[TBL] [Abstract][Full Text] [Related]
11.
Giunco S; Boscolo-Rizzo P; Rampazzo E; Tirelli G; Alessandrini L; Di Carlo R; Rossi M; Nicolai P; Menegaldo A; Carraro V; Tofanelli M; Bandolin L; Spinato G; Emanuelli E; Mantovani M; Stellin M; Bussani R; Dei Tos AP; Guido M; Morello M; Fussey J; Esposito G; Polesel J; De Rossi A
Front Oncol; 2021; 11():782658. PubMed ID: 34858860
[TBL] [Abstract][Full Text] [Related]
12. CTNNB1 mutations, TERT polymorphism and CD8+ cell densities in resected hepatocellular carcinoma are associated with longer time to recurrence.
Ambrozkiewicz F; Trailin A; Červenková L; Vaclavikova R; Hanicinec V; Allah MAO; Palek R; Třeška V; Daum O; Tonar Z; Liška V; Hemminki K
BMC Cancer; 2022 Aug; 22(1):884. PubMed ID: 35962322
[TBL] [Abstract][Full Text] [Related]
13. Acquired TERT promoter mutations stimulate TERT transcription in mantle cell lymphoma.
Panero J; Alves-Paiva RM; Roisman A; Santana-Lemos BA; Falcão RP; Oliveira G; Martins D; Stanganelli C; Slavutsky I; Calado RT
Am J Hematol; 2016 May; 91(5):481-5. PubMed ID: 26852175
[TBL] [Abstract][Full Text] [Related]
14. Polymorphisms in the telomerase reverse transcriptase promoter are associated with risk of breast cancer: A meta-analysis.
Li ZY; Dong YL; Feng Y; Zhang Z; Cao XZ
J Cancer Res Ther; 2016; 12(2):1040-4. PubMed ID: 27461695
[TBL] [Abstract][Full Text] [Related]
15. Large Multicohort Study Reveals a Prostate Cancer Susceptibility Allele at 5p15 Regulating
Dong X; Zhang Q; Hao J; Xie Q; Xu B; Zhang P; Lu H; Huang Q; Yang T; Wei GH; Na R; Gao P
Front Oncol; 2021; 11():754206. PubMed ID: 34858826
[TBL] [Abstract][Full Text] [Related]
16. Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes.
Labussière M; Boisselier B; Mokhtari K; Di Stefano AL; Rahimian A; Rossetto M; Ciccarino P; Saulnier O; Paterra R; Marie Y; Finocchiaro G; Sanson M
Neurology; 2014 Sep; 83(13):1200-6. PubMed ID: 25150284
[TBL] [Abstract][Full Text] [Related]
17. TERT Polymorphism rs2853669 Influences on Lung Cancer Risk in the Korean Population.
Yoo SS; Do SK; Choi JE; Lee SY; Lee J; Cha SI; Kim CH; Park JY
J Korean Med Sci; 2015 Oct; 30(10):1423-8. PubMed ID: 26425038
[TBL] [Abstract][Full Text] [Related]
18. Intratumoral heterogeneity and
Juratli TA; Thiede C; Koerner MVA; Tummala SS; Daubner D; Shankar GM; Williams EA; Martinez-Lage M; Soucek S; Robel K; Penson T; Krause M; Appold S; Meinhardt M; Pinzer T; Miller JJ; Krex D; Ely HA; Silverman IM; Christiansen J; Schackert G; Wakimoto H; Kirsch M; Brastianos PK; Cahill DP
Oncotarget; 2017 Dec; 8(65):109228-109237. PubMed ID: 29312603
[TBL] [Abstract][Full Text] [Related]
19. TERT promoter mutated WHO grades II and III gliomas are located preferentially in the frontal lobe and avoid the midline.
Sun ZL; Chan AK; Chen LC; Tang C; Zhang ZY; Ding XJ; Wang Y; Sun CR; Ng HK; Yao Y; Zhou LF
Int J Clin Exp Pathol; 2015; 8(9):11485-94. PubMed ID: 26617880
[TBL] [Abstract][Full Text] [Related]
20. TERT promoter mutations in clear cell renal cell carcinoma.
Hosen I; Rachakonda PS; Heidenreich B; Sitaram RT; Ljungberg B; Roos G; Hemminki K; Kumar R
Int J Cancer; 2015 May; 136(10):2448-52. PubMed ID: 25331263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
